M&T Bank
NGNE icon

M&T Bank’s Neurogene NGNE Stock Holding History

M&T Bank’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,138
Closed -$323K – 1631
2024
Q4 		$323K Buy
+14,138
New +$526K ﹤0.01% 1352

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

M&T Bank's NGNE Position: Q1 2025 in Review

M&T Bank sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 14,138 shares — an estimated $323K sold.

M&T Bank first reported a position in NGNE in Q4 2024 and held it in 1 quarter. The position peaked at $323K in Q4 2024. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • M&T Bank reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • M&T Bank sold 14,138 Neurogene shares in Q1 2025, an estimated $323K.
  • M&T Bank first reported a position in Neurogene in Q4 2024 and held it in 1 quarter.
  • M&T Bank's Neurogene position peaked at $323K in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on M&T Bank's 13F filing for Q1 2025, filed 30 Apr 2025.